{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T08:59:33Z","timestamp":1767085173404},"reference-count":50,"publisher":"Walter de Gruyter GmbH","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p id=\"P1_w2aab3b7c20b1b6b1aab1c16b1Aa\">Familial hypercholesterolemia (FH) is an autosomal dominant disorder resulting in severe elevation of total and low-density lipoprotein cholesterol levels. There are more than 600,000 individuals in the United States with FH. Individuals with FH tend to experience premature cardiovascular disease and often die from sudden cardiac death at a young age. Statins alone or in combination with other lipid-lowering medications are effective in managing FH and preventing cardiovascular events. For patients who do not respond to or are intolerant of pharmacotherapy, low-density lipoprotein apheresis is available as a nonpharmacologic treatment option. Despite the prevalence of FH, it is undiagnosed and untreated in the majority of patients. Screening, combined with appropriate drug therapy, can save lives. The authors review the screening, diagnosis, and management of FH.<\/jats:p>","DOI":"10.7556\/jaoa.2014.023","type":"journal-article","created":{"date-parts":[[2014,1,22]],"date-time":"2014-01-22T15:34:40Z","timestamp":1390404880000},"page":"99-108","source":"Crossref","is-referenced-by-count":13,"title":["Preventing Early Cardiovascular Death in Patients With Familial Hypercholesterolemia"],"prefix":"10.1515","volume":"114","author":[{"given":"Thomas B.","family":"Repas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Ross","family":"Tanner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2014,2,1]]},"reference":[{"key":"2021040108130486138_j_jaoa.2014.023_ref_001_w2aab3b7c20b1b6b1ab2b1b1Aa","unstructured":"KochanekKDXuJMurphySLMininoAMKungHDivision of Vital Statistics. Deaths: final data for 2009. Natl Vital Stat Rep.2011;60(3):1-117. http:\/\/www.cdc.gov\/nchs\/data\/nvsr\/nvsr60\/nvsr60_03.pdf. Accessed January 8, 2014."},{"key":"2021040108130486138_j_jaoa.2014.023_ref_002_w2aab3b7c20b1b6b1ab2b1b2Aa","unstructured":"FordESAjaniUACroftJB. Explaining the decrease in U.S. deaths from coronary disease, 1980\u20132000. N Engl J Med.2007;356(23):2388-2398. http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMsa053935. Accessed November 25, 2012."},{"key":"2021040108130486138_j_jaoa.2014.023_ref_003_w2aab3b7c20b1b6b1ab2b1b3Aa","unstructured":"UnalBCritchleyJACapewellS. Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2000[published online March 1, 2004]. Circulation. 2004;109(9):1101-1107. http:\/\/circ.ahajournals.org\/cgi\/pmidlookup?view=long&pmid=14993137. Accessed November 25, 2012."},{"key":"2021040108130486138_j_jaoa.2014.023_ref_004_w2aab3b7c20b1b6b1ab2b1b4Aa","doi-asserted-by":"crossref","unstructured":"CapewellSBeagleholeRSeddonMMcMurrayJ. Explanation for the decline in coronary heart disease mortality rates in Auckland, New Zealand, between 1982 and 1993. Circulation. 2000;102(13):1511-1516. http:\/\/circ.ahajournals.org\/content\/102\/13\/1511.long. Accessed November 25, 2012.","DOI":"10.1161\/01.CIR.102.13.1511"},{"key":"2021040108130486138_j_jaoa.2014.023_ref_005_w2aab3b7c20b1b6b1ab2b1b5Aa","doi-asserted-by":"crossref","unstructured":"LaatikainenTCritchleyJVartiainenESalomaaVKetonenMCapewellS. Explaining the decline in coronary heart disease mortality in Finland between 1982 and 1997. Am J Epidemiol.2005;162(8):764-773. http:\/\/aje.oxfordjournals.org\/content\/162\/8\/764.long. Accessed November 25, 2012.","DOI":"10.1093\/aje\/kwi274"},{"key":"2021040108130486138_j_jaoa.2014.023_ref_006_w2aab3b7c20b1b6b1ab2b1b6Aa","unstructured":"World Health Organization. Familial Hypercholesterolaemia (FH): Report of a Second WHO Consultation. Geneva, Switzerland: World Health Organization Human Genetics Programme; 1999. http:\/\/whqlibdoc.who.int\/hq\/1999\/WHO_HGN_FH_CONS_99.2.pdf. Accessed August 3, 2012."},{"issue":"3","key":"2021040108130486138_j_jaoa.2014.023_ref_007_w2aab3b7c20b1b6b1ab2b1b7Aa","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacl.2011.03.001","article-title":"Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia","volume":"5","author":"Goldberg","year":"2011","journal-title":"J Clin Lipidol."},{"issue":"5","key":"2021040108130486138_j_jaoa.2014.023_ref_008_w2aab3b7c20b1b6b1ab2b1b8Aa","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jacl.2010.08.022","article-title":"Defining the challenges of FH screening for familial hypercholesterolemia","volume":"4","author":"Defesche","year":"2010","journal-title":"J Clin Lipidol."},{"issue":"1","key":"2021040108130486138_j_jaoa.2014.023_ref_009_w2aab3b7c20b1b6b1ab2b1b9Aa","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.atherosclerosis.2003.11.010","article-title":"Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia","volume":"173","author":"Civeira","year":"2004","journal-title":"Atherosclerosis"},{"issue":"567","key":"2021040108130486138_j_jaoa.2014.023_ref_010_w2aab3b7c20b1b6b1ab2b1c10Aa","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3399\/bjgp09X472674","article-title":"Identification and management of familial hypercholesterolaemia: what does it mean to primary care?","volume":"59","author":"Qureshi","year":"2009","journal-title":"Br J Gen Pract."},{"key":"2021040108130486138_j_jaoa.2014.023_ref_011_w2aab3b7c20b1b6b1ab2b1c11Aa","unstructured":"YuanGWangJHegeleRA. Heterozygous familial hypercholesterolemia: an underrecognized cause of early cardiovascular disease. CMAJ. 2006;174(8):1124-1129. http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC1421462\/pdf\/20060411s00026p1124.pdf. Accessed August 3, 2012."},{"key":"2021040108130486138_j_jaoa.2014.023_ref_012_w2aab3b7c20b1b6b1ab2b1c12Aa","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1146\/annurev.ge.24.120190.001025","article-title":"The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein","volume":"24","author":"Hobbs","year":"1990","journal-title":"Annu Rev Genet."},{"issue":"4","key":"2021040108130486138_j_jaoa.2014.023_ref_013_w2aab3b7c20b1b6b1ab2b1c13Aa","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/MOL.0b013e32830636e5","article-title":"What is the clinical utility of DNA testing in patients with familial hypercholesterolaemia?","volume":"19","author":"Humphries","year":"2008","journal-title":"Curr Opin Lipidol."},{"key":"2021040108130486138_j_jaoa.2014.023_ref_014_w2aab3b7c20b1b6b1ab2b1c14Aa","doi-asserted-by":"crossref","unstructured":"Scientific Steering Committee on behalf of the Simon Broome Register Group. Risk of fatal coronary heart disease in familial hypercholesterolaemia. BMJ. 1991;303(6807):893-896. http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC1671226\/pdf\/bmj00148-0031.pdf. Accessed August 3, 2012.","DOI":"10.1136\/bmj.303.6807.893"},{"issue":"21","key":"2021040108130486138_j_jaoa.2014.023_ref_015_w2aab3b7c20b1b6b1ab2b1c15Aa","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1093\/eurheartj\/ehn422","article-title":"Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study","volume":"2","author":"Neil","year":"2008","journal-title":"Eur Heart J."},{"issue":"4","key":"2021040108130486138_j_jaoa.2014.023_ref_016_w2aab3b7c20b1b6b1ab2b1c16Aa","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1567-5688(01)00019-8","article-title":"High risk\/high priority: familial hypercholesterolemia\u2014a paradigm for molecular medicine","volume":"2","author":"Schuster","year":"2002","journal-title":"Atheroscler Suppl."},{"key":"2021040108130486138_j_jaoa.2014.023_ref_017_w2aab3b7c20b1b6b1ab2b1c17Aa","article-title":"Familial hypercholesterolemia: an under-recognized but significant concern in cardiology practice","author":"Foody","journal-title":"Clin Cardiol."},{"key":"2021040108130486138_j_jaoa.2014.023_ref_018_w2aab3b7c20b1b6b1ab2b1c18Aa","unstructured":"GrosseSDBoyleCABotkinJRCenters for Disease Control and Prevention. Newborn screening for cystic fibrosis. MMWR Recomm Report. 2004;53(RR-13):1-36. http:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/rr5313a1.htm. Accessed January 8, 2014."},{"issue":"9569","key":"2021040108130486138_j_jaoa.2014.023_ref_019_w2aab3b7c20b1b6b1ab2b1c19Aa","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","article-title":"Autosomal dominant polycystic kidney disease","volume":"369","author":"Torres","year":"2007","journal-title":"Lancet"},{"issue":"6","key":"2021040108130486138_j_jaoa.2014.023_ref_020_w2aab3b7c20b1b6b1ab2b1c20Aa","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1542\/peds.2009-0745","article-title":"Prevalence of Down syndrome among children and adolescents in 10 regions of the United States","volume":"124","author":"Shin","year":"2009","journal-title":"Pediatrics"},{"key":"2021040108130486138_j_jaoa.2014.023_ref_021_w2aab3b7c20b1b6b1ab2b1c21Aa","unstructured":"Diabetes Public Health Resource. Children and diabetes\u2014more information. Centers for Disease Control and Prevention website. http:\/\/www.cdc.gov\/diabetes\/projects\/cda2.htm. Accessed August 3, 2012."},{"key":"2021040108130486138_j_jaoa.2014.023_ref_022_w2aab3b7c20b1b6b1ab2b1c22Aa","unstructured":"CiveiraFCastilloSAlonsoR. Tendon xanthomas in familial hypercholesterolemia are associated with cardiovascular risk independently of the low-density lipoprotein receptor gene mutation[published online July 14, 2005]. Arterioscler Thromb Vasc Biol.2005;25(9):1960-1965. http:\/\/atvb.ahajournals.org\/content\/25\/9\/1960.full. Accessed November 25, 2012."},{"issue":"2","key":"2021040108130486138_j_jaoa.2014.023_ref_023_w2aab3b7c20b1b6b1ab2b1c23Aa","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0021-9150(01)00533-0","article-title":"The use of Achilles tendon ultrasonography for the diagnosis of familial hypercholesterolemia","volume":"157","author":"Descamps","year":"2001","journal-title":"Atherosclerosis"},{"issue":"9251","key":"2021040108130486138_j_jaoa.2014.023_ref_024_w2aab3b7c20b1b6b1ab2b1c24Aa","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0140-6736(00)03587-X","article-title":"Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands","volume":"357","author":"Umans-Eckenhausen","year":"2001","journal-title":"Lancet"},{"issue":"2","key":"2021040108130486138_j_jaoa.2014.023_ref_025_w2aab3b7c20b1b6b1ab2b1c25Aa","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0002-9149(93)90155-6","article-title":"Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics","volume":"72","author":"Williams","year":"1993","journal-title":"Am J Cardiol."},{"key":"2021040108130486138_j_jaoa.2014.023_ref_026_w2aab3b7c20b1b6b1ab2b1c26Aa","unstructured":"WiegmanARodenburgJde JonghS. Family history and cardiovascular risk in familial hypercholesterolemia: data in more than 1000 children. Circulation. 2003;107(11):1473-1478. http:\/\/circ.ahajournals.org\/content\/107\/11\/1473.full.pdf+html. Accessed August 3, 2012."},{"key":"2021040108130486138_j_jaoa.2014.023_ref_027_w2aab3b7c20b1b6b1ab2b1c27Aa","doi-asserted-by":"crossref","first-page":"a2423","DOI":"10.1136\/bmj.a2423","article-title":"Efficacy of statins in familial hypercholesterolaemia: a long term cohort study","volume":"337","author":"Versmissen","year":"2008","journal-title":"BMJ"},{"issue":"5","key":"2021040108130486138_j_jaoa.2014.023_ref_028_w2aab3b7c20b1b6b1ab2b1c28Aa","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jacl.2010.08.013","article-title":"Familial hypercholesterolemia: current treatment options and patient selection for low-density lipoprotein apheresis","volume":"4","author":"Hemphill","year":"2010","journal-title":"J Clin Lipidol."},{"issue":"19","key":"2021040108130486138_j_jaoa.2014.023_ref_029_w2aab3b7c20b1b6b1ab2b1c29Aa","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1161\/01.CIR.0000068312.21969.C8","article-title":"Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial","volume":"107","author":"Ballantyne","year":"2003","journal-title":"Circulation"},{"issue":"3","key":"2021040108130486138_j_jaoa.2014.023_ref_030_w2aab3b7c20b1b6b1ab2b1c30Aa","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1378\/chest.79.3.286","article-title":"Familial type II hyperlipoproteinemia with coronary heart disease: effect of diet-colestipol-nicotinic acid treatment","volume":"79","author":"Kuo","year":"1981","journal-title":"Chest"},{"key":"2021040108130486138_j_jaoa.2014.023_ref_031_w2aab3b7c20b1b6b1ab2b1c31Aa","unstructured":"McCrindleBWUrbinaEMDennisonBA. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation. 2007;115(14):1948-1967. http:\/\/circ.ahajournals.org\/content\/115\/14\/1948.full.pdf. Accessed August 3, 2012."},{"issue":"1","key":"2021040108130486138_j_jaoa.2014.023_ref_032_w2aab3b7c20b1b6b1ab2b1c32Aa","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ecl.2008.11.006","article-title":"Lipid management in children","volume":"38","author":"Zappalla","year":"2009","journal-title":"Endocrinol Metab Clin North Am."},{"issue":"1","key":"2021040108130486138_j_jaoa.2014.023_ref_033_w2aab3b7c20b1b6b1ab2b1c33Aa","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1542\/peds.2008-1349","article-title":"Lipid screening and cardiovascular health in childhood","volume":"122","author":"Daniels","year":"2008","journal-title":"Pediatrics"},{"key":"2021040108130486138_j_jaoa.2014.023_ref_034_w2aab3b7c20b1b6b1ab2b1c34Aa","unstructured":"de FerrantiSLudwigDS. Storm over statins\u2014the controversy surrounding pharmacologic treatment of children. N Engl J Med.2008;359(13):1309-1312. doi:10.1056\/NEJMp0805953. http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMp0805953. Accessed January 8, 2014."},{"issue":"3","key":"2021040108130486138_j_jaoa.2014.023_ref_035_w2aab3b7c20b1b6b1ab2b1c35Aa","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jacl.2008.04.008","article-title":"Pediatric dyslipidemias: prescription medication efficacy and safety","volume":"2","author":"Browne","year":"2008","journal-title":"J Clin Lipidol."},{"key":"2021040108130486138_j_jaoa.2014.023_ref_036_w2aab3b7c20b1b6b1ab2b1c36Aa","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0022-3476(03)00186-0","article-title":"Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial","volume":"143","author":"McCrindle","year":"2003","journal-title":"J Pediatr."},{"key":"2021040108130486138_j_jaoa.2014.023_ref_037_w2aab3b7c20b1b6b1ab2b1c37Aa","unstructured":"de JonghSOseLSzamosiT. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin. Circulation. 2002;106(17):2231-2237. http:\/\/circ.ahajournals.org\/content\/106\/17\/2231.full.pdf. Accessed January 8, 2014."},{"issue":"3","key":"2021040108130486138_j_jaoa.2014.023_ref_038_w2aab3b7c20b1b6b1ab2b1c38Aa","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/jama.292.3.331","article-title":"Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial","volume":"292","author":"Wiegman","year":"2004","journal-title":"JAMA"},{"issue":"5","key":"2021040108130486138_j_jaoa.2014.023_ref_039_w2aab3b7c20b1b6b1ab2b1c39Aa","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/01.crd.0000137736.74836.dd","article-title":"Nonpharmacologic approaches for the treatment of hyperlipidemia","volume":"13","author":"Kermani","year":"2005","journal-title":"Cardiol Rev."},{"issue":"4","key":"2021040108130486138_j_jaoa.2014.023_ref_040_w2aab3b7c20b1b6b1ab2b1c40Aa","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s11936-009-0029-1","article-title":"Low density lipoprotein apheresis as a treatment option for hyperlipidemia","volume":"11","author":"Mehta","year":"2009","journal-title":"Curr Treat Options Cardiovasc Med."},{"issue":"4","key":"2021040108130486138_j_jaoa.2014.023_ref_041_w2aab3b7c20b1b6b1ab2b1c41Aa","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1046\/j.1526-0968.2003.00070.x","article-title":"Low-density lipoprotein apheresis: an overview","volume":"7","author":"Bambauer","year":"2003","journal-title":"Ther Apher Dial"},{"key":"2021040108130486138_j_jaoa.2014.023_ref_042_w2aab3b7c20b1b6b1ab2b1c42Aa","unstructured":"American Society for Apheresis. Therapeutic Apheresis: A Guide to Billing and Securing Appropriate Reimbursement. Vancouver, British Columbia, Canada: American Society for Apheresis; 2013. http:\/\/www.apheresis.org\/resource\/resmgr\/files\/asfa_therapeutic_apheresis_r.pdf. Accessed January 8, 2014."},{"key":"2021040108130486138_j_jaoa.2014.023_ref_043_w2aab3b7c20b1b6b1ab2b1c43Aa","unstructured":"LIPOSORBER [package insert]. New York, NY: Kaneka Pharma America; 2010. http:\/\/www.liposorber.com\/physician\/prescribe\/prescribe.htm. Accessed March 12, 2011."},{"issue":"8","key":"2021040108130486138_j_jaoa.2014.023_ref_044_w2aab3b7c20b1b6b1ab2b1c44Aa","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.amjcard.2003.12.059","article-title":"Effect of low-density lipoprotein cholesterol apheresis on blood viscosity","volume":"93","author":"Moriarty","year":"2004","journal-title":"Am J Cardiol."},{"issue":"10","key":"2021040108130486138_j_jaoa.2014.023_ref_045_w2aab3b7c20b1b6b1ab2b1c45Aa","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.amjcard.2005.01.058","article-title":"Effect of low-density lipoprotein apheresis on lipoprotein-associated phospholipase A2","volume":"95","author":"Moriarty","year":"2005","journal-title":"Am J Cardiol."},{"issue":"2","key":"2021040108130486138_j_jaoa.2014.023_ref_046_w2aab3b7c20b1b6b1ab2b1c46Aa","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1526-0968.2003.00120.x","article-title":"State of the art of low-density lipoprotein apheresis in the year 2003","volume":"8","author":"Bosch","year":"2004","journal-title":"Ther Apher Dial"},{"key":"2021040108130486138_j_jaoa.2014.023_ref_047_w2aab3b7c20b1b6b1ab2b1c47Aa","unstructured":"MatsuzakiMHiramoriKImaizumiT. Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia. J Am Coll Cardiol.2002;40(2):220-227. http:\/\/content.onlinejacc.org\/article.aspx?articleid=1130199. Accessed August 3, 2012."},{"issue":"12","key":"2021040108130486138_j_jaoa.2014.023_ref_048_w2aab3b7c20b1b6b1ab2b1c48Aa","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0002-9149(98)00692-4","article-title":"Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia","volume":"82","author":"Mabuchi","year":"1998","journal-title":"Am J Cardiol."},{"issue":"5","key":"2021040108130486138_j_jaoa.2014.023_ref_049_w2aab3b7c20b1b6b1ab2b1c49Aa","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.amjcard.2004.05.051","article-title":"Long-term survival of childhood coronary artery disease in a patient severely affected with familial hypercholesterolemia","volume":"94","author":"Sibley","year":"2004","journal-title":"Am J Cardiol."},{"key":"2021040108130486138_j_jaoa.2014.023_ref_050_w2aab3b7c20b1b6b1ab2b1c50Aa","unstructured":"Patient information from the Foundation of the National Lipid Association. Learn Your Lipids website. http:\/\/www.learnyourlipids.com. Accessed August 3, 2012."}],"container-title":["Journal of Osteopathic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.7556\/jaoa.2014.023\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.7556\/jaoa.2014.023\/html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T08:21:18Z","timestamp":1617265278000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.7556\/jaoa.2014.023\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,1]]},"references-count":50,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2014,2,1]]},"published-print":{"date-parts":[[2014,2,1]]}},"alternative-id":["10.7556\/jaoa.2014.023"],"URL":"https:\/\/doi.org\/10.7556\/jaoa.2014.023","relation":{},"ISSN":["2702-3648"],"issn-type":[{"value":"2702-3648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,1]]}}}